Melanoma-associated antigen 1 (MAGEA1) (MAGEA1)

Melanoma-associated antigen 1 (MAGEA1) is a pioneering member of the cancer-testis antigen (CTA) family, originally identified in melanoma patients [PMID: 1840448]. It is characterized by a highly restricted expression pattern, being found only in the immune-privileged cells of the testis and placenta in healthy individuals, but frequently overexpressed in a wide range of malignancies including lung, breast, and liver cancers [UniProt: P43355]. Biologically, MAGEA1 functions as a transcriptional regulator and a scaffold for E3 ubiquitin ligases, such as TRIM28, thereby influencing protein degradation pathways and cellular signaling [PMID: 25635344]. Due to its tumor-specific expression, MAGEA1 is a prominent target for cancer immunotherapy, particularly for T-cell receptor (TCR) engineered T-cell therapies and cancer vaccines designed to elicit a cytotoxic T-cell response [PMID: 31534003]. Therapeutic development focuses on identifying specific HLA-restricted peptides of MAGEA1 to ensure precise targeting of malignant cells while minimizing the risk of autoimmune reactions in normal tissues. As a biomarker, its presence is often used to select patients for clinical trials involving MAGE-targeted agents, although challenges such as antigen heterogeneity and tumor immune evasion through HLA downregulation remain significant hurdles.

Other names

MAGE1MAGE-1Melanoma antigen family A 1Cancer/testis antigen 1.1CT1.1Antigen MZ2-E

Induction of antigen-specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing MAGEA1 peptides in the context of MHC class I molecules.